
MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.
Learn moreWe don't have the page you're looking for.
Please select one of the pages below.
Homepage
About Us
Approach
Capabilities
Management Team
Board of Directors
Pipeline
Teplizumab (Anti-CD3)
MGAWN1 (WNV)
MGAH22 (Anti-HER2)
Other
Platforms
Dual-Affinity Re-Targeting
Cancer Stem Cells
Fc Optimization
Partnering
Collaborators
News & Media
Press Releases
In the News
E-Mail Alerts
Media Kit / Downloads
Publications
Careers
Employee Benefits
Contact Us
Search